As Eli Lil­ly's Moun­jaro pre­scrip­tions sky­rock­et, an­a­lyst pre­dicts $50B in year­ly tirzepatide sales

No mat­ter how you look at it, the obe­si­ty drug mar­ket is shap­ing up to be vast. And the spot­light right now is on Eli Lil­ly’s tirzepatide, which was ap­proved last year as Moun­jaro for type 2 di­a­betes and is al­ready un­der rolling sub­mis­sion as an obe­si­ty treat­ment.

The cur­rent flur­ry of in­ter­est comes in ad­vance of new da­ta ex­pect­ed this month from its sec­ond SUR­MOUNT study at the same time that Moun­jaro pre­scrip­tions are sky­rock­et­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.